<DOC>
	<DOCNO>NCT02037737</DOCNO>
	<brief_summary>The purpose study ass Abatacept Intravenous ( IV ) effectiveness patient inadequate response one conventional Disease Modifying Against Rheumatism ( DMARDs ) include Methotrexate France , estimation Abatacept retention rate 2 year reason discontinuation</brief_summary>
	<brief_title>Impact Use Abatacept IV Rheumatoid Arthritis Real Life Setting</brief_title>
	<detailed_description>Observational Model : Other : ReACTION study use secondary data originally collect ACTION study . In ACTION , data collect prospectively October 2010 2015 clinical visit . In France , data collection start June 2011</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>All patient enrol ACTION inadequate response one conventional DMARDs include Methotrexate treat Abatacept IV include ReACTION ACTION inclusion criterion France : Male female subject 18 year old Patients diagnosis establish moderate severe active RA Patients physician 's discretion treat Abatacept ( initiate already treatment within 3 month ) accord routine clinical practice Patients baseline characteristic available Patients consent usage data ACTION study Patients include interventional clinical trial RA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>